# Hallmarks of cancer as a synthesis of the theories

Source: https://onco.cc/terms/hallmarks-synthesis/  
OnCo record `hallmarks-synthesis` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rather than asking what starts cancer, Hanahan and Weinberg asked what every cancer ends up able to do: keep growing, ignore stop signals, avoid death, live forever, grow vessels, invade, rewire metabolism and hide from the immune system. Each update has absorbed a rival theory into the list, so the hallmarks read as the field's working synthesis rather than a theory of cause.

## Summary

The claim. Whatever their origin, cancers converge on a shared set of acquired functional capabilities. The 2000 paper listed six: sustaining proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. The 2011 update added reprogramming energy metabolism and evading immune destruction, and named two enabling characteristics: genome instability and mutation, and tumour-promoting inflammation, with the tumour microenvironment as a full participant. Hanahan's 2022 paper added unlocking phenotypic plasticity, non-mutational epigenetic reprogramming, polymorphic microbiomes and senescent cells.

Who and when. Douglas Hanahan and Robert Weinberg, Cell 2000 and 2011; Hanahan alone in Cancer Discovery 2022. The papers are among the most cited in biology.

Evidence for. Each hallmark corresponds to a pathway and to a drug class that acts on it: CDK4/6 inhibitors for evading growth suppressors, BCL-2 inhibitors for resisting cell death, anti-VEGF antibodies for angiogenesis, checkpoint inhibitors for immune evasion, IDH inhibitors for metabolism, telomerase inhibition with imetelstat for replicative immortality. The framework organises teaching, drug discovery portfolios and, on this site, the mechanics atlas.

Evidence against and limits. Lazebnik's 2010 critique noted that benign tumours display most of the hallmarks and that only invasion and metastasis separate malignant from benign, so the list describes neoplasia more than cancer. Sonnenschein and Soto argue that the hallmarks are cell-centred and circular: they redescribe what cancer cells do without saying why a tissue produced them. The list is not predictive; it did not anticipate immunotherapy's clinical success (immune evasion entered only in 2011, after the first checkpoint trials) and it says nothing about the order of events or about prevention. Critics also observe that a list that grows with each update cannot be falsified.

Predictions that held or failed. Held: hallmark-directed drug classes exist for every core hallmark. Failed or qualified: the 2000 paper's expectation that anti-angiogenic therapy would be broadly curative was not met (bevacizumab adds months, not cures), and hallmark-directed monotherapies are rarely curative because tumours use the other hallmarks to compensate.

How it relates to the other theories. It sits at the end of the mainstream trunk (somatic mutation, drivers, clonal evolution) and has absorbed the microenvironment and inflammation view (2011), the immune surveillance view (2011), the metabolic view (2011) and the epigenetic and plasticity views (2022). The tissue organisation field theory and the atavistic theory remain outside it and criticise it.

Status: established as a framework and a vocabulary, not as a theory of cause. Its own authors call it a heuristic; its usefulness is in mapping mechanisms to medicines, which is how OnCo uses it.

## Fields

- Kind: Term
- Last checked: 2026-09-17
- Also known as: hallmarks framework; hallmarks as synthesis; Hanahan and Weinberg framework
- Tags: theory

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/The_Hallmarks_of_Cancer
- Hanahan and Weinberg, The hallmarks of cancer (Cell 2000): https://doi.org/10.1016/S0092-8674(00)81683-9
- Hanahan and Weinberg, Hallmarks of cancer: the next generation (Cell 2011): https://doi.org/10.1016/j.cell.2011.02.013
- Hanahan, Hallmarks of Cancer: New Dimensions (Cancer Discovery 2022): https://doi.org/10.1158/2159-8290.CD-21-1059
- Lazebnik, What are the hallmarks of cancer? (Nature Reviews Cancer 2010): https://doi.org/10.1038/nrc2827

## Connected records

- pathways: [Cancer metabolism](https://onco.cc/pathways/cancer-metabolism/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [Telomere maintenance & replicative immortality](https://onco.cc/pathways/telomere-maintenance/), [Theories of cancer: how the ideas connect](https://onco.cc/pathways/theories-of-cancer/), [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- terms: [Aneuploidy and chromosomal instability as the cause of cancer](https://onco.cc/terms/aneuploidy-theory-of-cancer/), [Atavistic theory: cancer as a reversion to an ancient programme](https://onco.cc/terms/atavistic-theory-of-cancer/), [Cancer stem cell theory and phenotypic plasticity](https://onco.cc/terms/cancer-stem-cell-theory/), [Clonal evolution and the ecological view of cancer](https://onco.cc/terms/clonal-evolution-theory/), [Enabling characteristic: genome instability and mutation](https://onco.cc/terms/genome-instability-mutation/), [Enabling characteristic: tumour-promoting inflammation](https://onco.cc/terms/tumor-promoting-inflammation/), [Epigenetic progenitor theory: cancer without a first mutation](https://onco.cc/terms/epigenetic-progenitor-theory/), [Hallmark (2022): non-mutational epigenetic reprogramming](https://onco.cc/terms/nonmutational-epigenetic-reprogramming/), [Hallmark (2022): polymorphic microbiomes](https://onco.cc/terms/polymorphic-microbiomes/), [Hallmark (2022): senescent cells](https://onco.cc/terms/senescent-cells/), [Hallmark (2022): unlocking phenotypic plasticity](https://onco.cc/terms/unlocking-phenotypic-plasticity/), [Hallmark: activating invasion and metastasis](https://onco.cc/terms/activating-invasion-metastasis/), [Hallmark: avoiding immune destruction](https://onco.cc/terms/avoiding-immune-destruction/), [Hallmark: evading growth suppressors](https://onco.cc/terms/evading-growth-suppressors/), [Hallmark: inducing or accessing vasculature](https://onco.cc/terms/inducing-angiogenesis/), [Hallmark: reprogramming cellular metabolism](https://onco.cc/terms/deregulating-cellular-energetics/), [Hallmark: resisting cell death](https://onco.cc/terms/resisting-cell-death/), [Hallmark: sustaining proliferative signalling](https://onco.cc/terms/sustaining-proliferative-signaling/), [Hallmarks of Cancer](https://onco.cc/terms/hallmarks-of-cancer/), [Immune surveillance and cancer immunoediting](https://onco.cc/terms/immune-surveillance-immunoediting/), [Metabolic theory of cancer: from Warburg to oncometabolites](https://onco.cc/terms/metabolic-theory-of-cancer/), [Microenvironment and inflammation: tumours as wounds that do not heal](https://onco.cc/terms/microenvironment-inflammation-theory/), [Somatic mutation theory of cancer](https://onco.cc/terms/somatic-mutation-theory/), [Tissue organisation field theory (Sonnenschein and Soto)](https://onco.cc/terms/tissue-organisation-field-theory/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Imetelstat](https://onco.cc/drugs/imetelstat/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- key papers: [Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells](https://onco.cc/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/), [The Hallmarks of Cancer: six capabilities every tumour must acquire](https://onco.cc/key-papers/paper-hallmarks-of-cancer-cell-2000/)

---
JSON: https://onco.cc/api/v1/entities/hallmarks-synthesis.json